Drug intelligence / Profile preview

edoxaban

Development stage: Approved
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Oral

Overview

Edoxaban is an oral anticoagulant belonging to the class of direct factor Xa inhibitors. It is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) after initial therapy with a parenteral anticoagulant. Edoxaban works by selectively inhibiting factor Xa, a key enzyme in the coagulation cascade, thereby decreasing blood clot formation. The drug was developed by Daiichi Sankyo[3][6].

Brand names: SavaysaLixiana
Other names: edoxaban tosylateedoxabanum

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on edoxaban.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on edoxaban.

Explore the full profile